Intravenous Solutions Market

Intravenous Solutions Market Outlook (2022-2032)

The global Intravenous Solutions Market was valued at around US$ 10.9 Bn in 2021. With a projected CAGR of 10.8% for the next ten years, the market is likely to reach a valuation of nearly US$ 33.6 Bn by the end of 2032. The demand for Intravenous solutions is anticipated to increase in the coming years due to the sedentary lifestyle of about 39% of the world population, particularly among the aging population as a result of chronic conditions like cancer, heart disease, stroke, diabetes, and arthritis.

Persistence Market Research’ analysis reveals that in 2022 revenue through the Intravenous Solutions Market is estimated at US$ 12.1 Bn. Worldwide, there has been a growing need for intravenous (IV) solutions. It is crucial because it provides patients in the ICU with the necessary nutrients. Higher efficacy is correlated with a quicker response time. Therapy with intravenous solutions makes a significant contribution to the market's expansion.

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Get FREE Report Sample

Sales Analysis of Intravenous Solutions Market from 2017 to 2021 Vs Market Outlook for 2022 to 2032

The global market for the Intravenous Solutions Market expanded at a CAGR of 10% during 2017-2021. As per the Faculty of Health Centre for Rural Health (Australia), more than 75% of patients admitted to hospitals are receiving some type of IV therapy. The United States will continue to be the largest consumer of Intravenous Solutions throughout the analysis period accounting for over US$ 8.8 Bn absolute dollar opportunity in the coming 10-year period.

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

Get a Customized Version

What are the Key Drivers for the Intravenous Solutions Market?

Severe dehydration is one of the main conditions for which intravenous (IV) fluids are used. Diseases like diarrhea, which cause the body's fluid reserves to be depleted, can cause severe dehydration. The WHO reports that in 2017, diarrhea accounted for around 525 thousand annual deaths among children under the age of five, making it the second greatest cause of mortality in this age group. Intravenous (IV) fluids can be extremely helpful in the treatment and in averting fatalities brought on by disease-related dehydration and fluid loss. Surgery and emergency scenarios are two more situations where intravenous fluids are used extensively.

The rate of premature births has been steadily rising. One in ten babies born in the nation in 2019 suffered from premature birth. Proteins, calories, and electrolytes are present in the fluid. Thus, it is anticipated that there will be a rise in demand for IV solutions along with a rise in preterm births.

Cost savings have been associated with standard intravenous solutions. A reduction in administering supplies and nursing time is responsible for the lower cost. Although normal (0.9%) saline is typically less expensive than colloid preparations and some buffered salt solutions, the cost of intravenous fluid varies significantly between fluid types and nations. When compared to the 2-in-1 plus a separate IVFE injection, the nursing time is cut in half (2.2 vs. 4.3 hours) for a common intravenous solution administering process.

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

How Covid-19 Impacted the intravenous solutions market?

The need for intravenous solutions increased significantly during the pandemic. Patients infected with COVID-19 are overflowing Intensive Care Units (ICU) all over the world. Additionally, the WHO has advised that patients with COVID-19 who are experiencing respiratory failure should be given intravenous fluids, particularly in situations when mechanical ventilation is being used.

As a result, an increase in IV solution demand is anticipated in the forthcoming years. According to a BBC article, critical care wards in England operated at max capacity in Jan 2021. One of the key components in handling these individuals is nutritional care. Because many patients, particularly the older population, are put on ventilators and are unable to swallow food, this has raised the demand for intravenous fluids.

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert

I'm Available

Region-wise Insights

Why Intravenous Solutions Market in Asia Pacific is Projected to Offer Significant Oppotrunity?

The market in Asia Pacific is projected to register the fastest growth with a projected CAGR of over 11%. China and India account for more than 3.5 Mn preterm births annually, or 24% of all preterm births worldwide. Premature babies are more likely to experience poor growth and illnesses. Therefore, early parenteral nutrition is essential for preterm infants and must provide enough energy and amino acids. This is anticipated to drive the Asia Pacific intravenous (IV) solutions market in the years to come.

Country-wise Insights

U.S. Intravenous Solutions Market Analysis

The United States will account for US$ 8.8 Bn absolute dollar opportunity in the Intravenous Solutions Market during 2022 - 2032. Intravenous Solutions Market growth in the U.S. from 2022 to 2032 is projected at 12.2% CAGR. Due to frequent influenza cases, the demand for intravenous (IV) medications has elevated in the country.

U.K. Intravenous Solutions Market Analysis

The Intravenous Solutions Market in the U.K. is projected to swell at a CAGR of 11.3% during the forecast period. The market is expected to reach a valuation of US$ 1.4 Bn by 2032, registering an absolute dollar opportunity of US$ 894 Mn during 2022 – 2032.

Japan Intravenous Solutions Market Analysis

In Japan, the Intravenous Solutions Market is expected to reach US$ 1.4 Bn by 2032. With an absolute dollar opportunity of US$ 835 Mn during 2022 – 2032, the market is projected to garner a CAGR of 9.8%.

South Korea Intravenous Solutions Market Analysis

The intravenous Solutions Market in South Korea is expected to register an absolute dollar opportunity of US$ 344 Mn. With a CAGR of 7.7% during 2022 – 2032, the market is expected to reach a size of US$ 645 Mn.

Category-wise Insights

Why is Total Parenteral Nutrition (TPN) the Preferred Type in the Intravenous Solutions Market?

The intravenous Solutions Market through the Total Parenteral Nutrition (TPN) segment expanded at a CAGR of 10.3% during 2017-2021. The expanding importance in the treatment of long-term inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, which afflict over 1.6 Mn individuals annually in the US has been pivotal to the market growth through Total Parenteral Nutrition. Total Parenteral Nutrition (TPN) is used to treat malnutrition and maintain proper nutrition in the body. It causes negative effects in less than 1% of patients. It is so widely utilized and controls the majority of the market in its sector.

Competitive Landscape

Intravenous Solution providers are setting up joint ventures and acquiring specialized sister companies, and aiming to get FDA approval for their products. The key companies operating in the Intravenous Solutions Market include Fresenius Kabi, Otsuka Pharmaceutical Co., Terumo Corporation, Baxter International Inc, B. Braun Melsungen AG, ICU Medical, Inc, Grifols, S.A., Amanta Healthcare, Axa Parenterals Ltd, and Salius Pharma Private Limited, Vifor Pharma Management Ltd, JW Life Science, Ajinomoto Health & Nutrition North America, Inc., Hospira, Terumo Corporation.

Some of the recent developments by key providers of the Intravenous Solutions Market are as follows:

• In May 2022, Ivenix, Inc. announced that it is fully acquired by Fresenius Kabi, creating a market-leading infusion treatment service in the United States. Infusion devices and intravenous fluids from Fresenius Kabi will be combined with industry-leading technology and software from Ivenix to produce a full and innovative lineup of premium goods. This creates a solid, quick foundation for long-term growth in the high-value MedTech sector.
• In February 2022, the new IV saline solution production facility owned by B. Braun Medical in Florida, USA, has been given the go-ahead by the US FDA.
• In September 2021, B. Braun Medical Inc announced the introduction of CARESAFE IV Administration Sets with an Optional AirStop component.
• In February 2020, in order to provide patients access to crucial blood management treatments, Fresenius Kabi and Vifor Pharma established a joint venture in China. To benefit both patients and the Chinese healthcare system, it will combine Fresenius Kabi's strong and long-standing market presence with Vifor Pharma's leading intravenous medication portfolio for the treatment of iron deficiency. Vifor Pharma will control 55% of the combined firm, and Fresenius Kabi will own the remaining 45%.
• In June 2020, to sell its parenteral nutrition (PN) products in the American market, JW Holdings partnered with Baxter. Parenteral nutrition (PN) was created for Baxter in accordance with the conditions of the contract by JW Life Science, a division of JW Holdings. The agreement is anticipated to assist in closing the gap between the country's supply and demand for intravenous solutions.

Similarly, recent developments related to companies manufacturing Intravenous solutions have been tracked by the team at Persistence Market Research, which is available in the full report.

Key Segments Covered in Intravenous Solutions Market Survey

By Type:

• Total Parenteral Nutrition (TPN)
• Peripheral Parenteral Nutrition (PPN)

By Nutrients:

• Carbohydrates
• Single Dose Amino Acid Solution
• Vitamins & Minerals (Salt and Electrolyte)
• Parenteral Lipid Emulsion
• Other Nutrients

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa